Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Vatelizumab in Ulcerative Colitis
NCT01861249Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jul 2013
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vatelizumab in ulcerative colitis (UC), sponsored by Sanofi. Primary endpoint: Percentage of participants with Adverse Events. Started Jul 2013; status: terminated.
02
Drugs
vatelizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01861249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861249.